Condition (MeSH)
Embolism, Cholesterol
ClinicalTrials.gov lists 2 trials for Embolism, Cholesterol or a narrower condition beneath it. National Heart, Lung, and Blood Institute (NHLBI) has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
2 of the 2 trials are tagged with Embolism, Cholesterol itself; the rest are tagged with a narrower condition beneath it.
When did Embolism, Cholesterol trials start? (2)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2013 | 1 |
| 2001 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 2 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Embolism, Cholesterol trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
How many Embolism, Cholesterol trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Embolism, Cholesterol trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | 1 |
Which publications cover Embolism, Cholesterol? (9)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Efficacy of LDL apheresis for the treatment of cholesterol crystal embolism: A prospective, controlled study. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy | 2022 | Yes |
| Embolization of Neoatherosclerosis After Percutaneous Coronary Intervention: Insights From Near-Infrared Spectroscopy Imaging and Histopathological Analysis. | Circulation. Cardiovascular interventions | 2018 | Yes |
| [Neurological manifestation of multiple cholesterol embolization syndrome: Value of MRI diffusion sequence]. | Revue neurologique | 2013 | Yes |
| Intraplaque haemorrhages as the trigger of plaque vulnerability. | European heart journal | 2011 | Yes |
| Incidence of atheroembolic renal failure after coronary angiography. A prospective study. | Angiology | 1997 | Yes |
Showing 5 of 9 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.